Testosterone and Prostate Cancer

European Urology

Volumn 51, Issue 2, 2007, Pages 293-295

  Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ESTROGEN; GONADORELIN AGONIST; TESTOSTERONE; TESTOSTERONE PROPIONATE;

ACID PHOSPHATASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; CASTRATION; EDITORIAL; ESTROGEN THERAPY; HUMAN; HYPOGONADISM; METASTASIS; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 33845565174     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.048     Document Type: Editorial

References (11)

1. Huggins C., and Hodge G.B. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Debruyne F.M.J., Akaza H., Mahler C., et al. Innovative approaches in medical management of prostate cancer. Hormones (2003) 139-158
3. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935-939
4. Kuhn J.M., Billebaud T., Navratil H., et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321 (1989) 413-418
5. Fowler J.E., and Whitmore Jr. W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126 (1981) 372-375
6. Severi G., Morris H.A., MacInnis R.J., et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 86-91
7. Freedland S.J., Platz E.A., Presti Jr. J.C., et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175 (2006) 500-504
8. Teloken C., Da Ros C.T., Caraver F., Weber F.A., Cavalheiro A.P., and Graziottin T.M. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178-2180
9. Harper M.E., Wilson D.W., Jensen H.M., Pierrepoint C.G., and Griffiths K. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade. J Steroid Biochem 27 (1987) 521-524
10. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
11. Yano M., Imamoto T., Suzuki H., et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 51 (2007) 375-380